KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesDeferred RevenueEmployee StatisticsGovernment Contracts Revenue By CategoryGrants And Other Revenue By CategoryGrants And Other Revenue By Category AnnualGross Margin %Gross ProfitIncome (Loss) Before Income TaxOperating Expense SegregationOpex As % Of Total Revenue %Product Sales Revenue By GeographyProduct Sales Revenue By Geography AnnualProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownPurchase Commitments AnnualRemaining Performance ObligationRemaining Performance Obligations AnnualRevenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Gross Profit: 2009-2024

Historic Gross Profit for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $479.4 million.

  • Novavax's Gross Profit rose 104.87% to $48.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $912.8 million, marking a year-over-year increase of 61.80%. This contributed to the annual value of $479.4 million for FY2024, which is 25.08% down from last year.
  • Latest data reveals that Novavax reported Gross Profit of $479.4 million as of FY2024, which was down 25.08% from $639.9 million recorded in FY2023.
  • Over the past 5 years, Novavax's Gross Profit peaked at $1.1 billion during FY2021, and registered a low of $475.6 million during FY2020.
  • Its 3-year average for Gross Profit is $732.9 million, with a median of $639.9 million in 2023.
  • In the last 5 years, Novavax's Gross Profit skyrocketed by 2,448.48% in 2020 and then tumbled by 40.70% in 2023.
  • Novavax's Gross Profit (Yearly) stood at $475.6 million in 2020, then spiked by 141.02% to $1.1 billion in 2021, then declined by 5.85% to $1.1 billion in 2022, then slumped by 40.70% to $639.9 million in 2023, then decreased by 25.08% to $479.4 million in 2024.